Adipose-Derived Mesenchymal Stem Cells for Treatment of Airway Injuries in A Patient after Long-Term Exposure to Sulfur Mustard

(Pages: 117-126)
Amir Nejad-Moghaddam, Ph.D, 1Soheila Ajdari, Ph.D, 2Eisa Tahmasbpour, Ph.D, 1Hassan Goodarzi, M.D, 1Yunes Panahi, Ph.D, 1Mostafa Ghanei, M.D, 1,*
Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
Department of Immunology, Pasteur Institute of Iran, Tehran, Iran
Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
Department of Immunology, Pasteur Institute of Iran, Tehran, Iran
* Corresponding Address: P.O.Box: 1435916471 Chemical Injuries Research Center Baqiyatallah University of Medical Sciences Mollasadra Street Tehran Iran Email:m.ghanei@bmsu.ac.ir
Any use, distribution, reproduction or abstract of this publication in any medium, with the exception of commercial purposes, is permitted provided the original work is properly cited This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Nejad-Moghaddam Amir, Ajdari Soheila, Tahmasbpour Eisa, Goodarzi Hassan, Panahi Yunes, Ghanei Mostafa. Adipose-Derived Mesenchymal Stem Cells for Treatment of Airway Injuries in A Patient after Long-Term Exposure to Sulfur Mustard . Cell J. 2017; 19(1): 117-126.

Abstract

Objective

Sulfur mustard (SM) is a potent mutagenic agent that targets several organs, particularly lung tissue. Changes in morphological structure of the airway system are associated with chronic obstructive pulmonary deficiency following exposure to SM. Although numerous studies have demonstrated pathological effects of SM on respiratory organs, unfortunately there is no effective treatment to inhibit further respiratory injuries or induce repair in these patients. Due to the extensive progress and achievements in stem cell therapy, we have aimed to evaluate safety and potential efficacy of systemic mesenchymal stem cell (MSC) administration on a SM-exposed patient with chronic lung injuries.

Materials and Methods

In this clinical trial study, our patient received 100×106cells every 20 days for 4 injections over a 2-month period. After each injection we evaluated the safety, pulmonary function tests (PFT), chronic obstructive pulmonary disease (COPD) Assessment Test (CAT), St. George’s Respiratory Questionnaire (SGRQ), Borg Scale Dyspnea Assessment (BSDA), and 6 Minute Walk Test (6MWT). One-way ANOVA test was used in this study which was not significant (P>0.05).

Results

There were no infusion toxicities or serious adverse events caused by MSC administration. Although there was no significant difference in PFTs, we found a significant improvement for 6MWT, as well as BSDA, SGRQ, and CAT scores after each injection.

Conclusion

Systemic MSC administration appears to be safe in SM-exposed patients with moderate to severe injuries and provides a basis for subsequent cell therapy investigations in other patients with this disorder (Registration Number: IRCT2015110524890N1).